

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.



天津泰達生物醫學工程股份有限公司

Tianjin TEDA Biomedical Engineering Company Limited

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 8189)

COMPLETION OF SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE

Reference is made to the announcements of Tianjin TEDA Biomedical Engineering Company Limited (天津泰達生物醫學工程股份有限公司) (the “**Company**”) dated 9 February 2018 and 12 February 2018 (the “**Announcements**”) in respect of the Subscription. Capitalised terms used herein shall have the same meanings as those defined in the Announcements unless otherwise stated.

COMPLETION OF THE SUBSCRIPTION

The Board is pleased to announce that the conditions set out in the Subscription Agreements have been fulfilled and the completion of the Subscription took place on 14 March 2018. Pursuant to the Subscription Agreements, an aggregate of 199,500,000 Subscription Shares, representing approximately 10.53% of the issued share capital of the Company as enlarged by the Subscription Shares, have been allotted and issued by the Company to the Subscribers at the Subscription Price of HK\$0.25 per Subscription Share.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, save for their respective holdings of the Subscription Shares upon completion, the Subscribers and their ultimate beneficial owner(s) (as the case may be) are Independent Third Parties.

The net proceeds from the Subscription after deducting relevant expenses incurred in relation to the Subscription, amount to approximately HK\$49,225,000 which is intended to be used by the Company for further development of its overall planning of the business fields including but not limited to elderly care services and the operation and management business integrating medical and care services, such as the improvement of the custodial services, facilities and information management of the elderly care institutions, etc.

EFFECTS ON THE SHAREHOLDING STRUCTURE OF THE COMPANY

Set out below is the shareholding structure of the Company immediately before and after the completion of the Subscription:

Holders of Domestic Shares or H Shares	Immediately before the completion of the Subscription		Immediately after the completion of the Subscription	
	<i>Number of Shares</i>	<i>%</i>	<i>Number of Shares</i>	<i>%</i>
<i>Domestic Shares</i>				
Tianjin TEDA International Incubator	182,500,000	10.77	182,500,000	9.63
Shenzhen Xiangyong Investment Company Limited	180,000,000	10.62	180,000,000	9.50
Shandong Zhinong Fertilizers Company Limited	180,000,000	10.62	180,000,000	9.50
Dongguan Lvye Fertilizers Company Limited	120,000,000	7.08	120,000,000	6.33
others	35,000,000	2.06	35,000,000	1.85
<i>H shares</i>				
Shu Ju Ku Inc.	100,000,000	5.9	100,000,000	5.28
Public Shareholders	897,500,000	52.95	897,500,000	47.38
Subscribers	–	–	199,500,000	10.53
Total	<u>1,695,000,000</u>	<u>100.00</u>	<u>1,894,500,000</u>	<u>100.00</u>

By order of the Board

Tianjin TEDA Biomedical Engineering Company Limited

Sun Li

Chairman

Tianjin, the PRC
14 March 2018

As at the date of this announcement, the executive Directors of the Company are Sun Li, Hao Zhihui and Liu Renmu; the non-executive Directors of the Company are Cao Aixin, Feng Enqing, and Li Ximing; the independent non-executive Directors of the Company are Li Xudong, Wang Yongkang and Gao Chun.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the GEM website at www.hkgem.com on the “Latest Company Announcements” page for 7 days from the date of its posting, and it will also be published and remain on the website of the Company at www.bioteda.com.